Remicade(Infliximab for Injection) is a prescription biologic licensed on February 15, 2007. Its approved indications include the treatment of moderate-to-severe active rheumatoid arthritis (administered in combination with methotrexate), moderate-to-severe active Crohn's disease refractory to conventional therapy (including fistulizing disease), active ankylosing spondylitis, and chronic severe plaque psoriasis unresponsive to systemic treatments.

AccuSift provides high-performance competitive antibody pairs for infliximab detection. These reagents offer exceptional inter-batch consistency and are optimized specifically for IVD kit development, including lateral flow assays, chemiluminescence, ELISA, and POCT platforms. Featuring high affinity and high specificity, they enable rapid and reliable detection.

Sensitivity: ELISA LOD: 100 ng/mL